ADXS31-142, intended for the treatment of prostate cancer, was engineered to secrete a fusion of LLO and prostate specific antigen (a serine protease that displays elevated levels during prostate cancer progression) (Hannan et al., 2012). Here, KLK3 is linked to prostate carcinoma.